Jennifer A. Grabowsky

799 total citations
29 papers, 634 citations indexed

About

Jennifer A. Grabowsky is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jennifer A. Grabowsky has authored 29 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 14 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jennifer A. Grabowsky's work include Histone Deacetylase Inhibitors Research (9 papers), Renal cell carcinoma treatment (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). Jennifer A. Grabowsky is often cited by papers focused on Histone Deacetylase Inhibitors Research (9 papers), Renal cell carcinoma treatment (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). Jennifer A. Grabowsky collaborates with scholars based in United States, Canada and Germany. Jennifer A. Grabowsky's co-authors include Pamela N. Münster, Michael P. Manns, Stephan C. Bischoff, Rahul Aggarwal, Scott Thomas, Alan P. Venook, Adil Daud, Jim Leng, Nela Pawłowska and Robin Kate Kelley and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Jennifer A. Grabowsky

29 papers receiving 623 citations

Peers

Countries citing papers authored by Jennifer A. Grabowsky

Since Specialization

Citations

This map shows the geographic impact of Jennifer A. Grabowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer A. Grabowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer A. Grabowsky more than expected).

Fields of papers citing papers by Jennifer A. Grabowsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer A. Grabowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer A. Grabowsky. The network helps show where Jennifer A. Grabowsky may publish in the future.

Co-authorship network of co-authors of Jennifer A. Grabowsky

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer A. Grabowsky. A scholar is included among the top collaborators of Jennifer A. Grabowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer A. Grabowsky. Jennifer A. Grabowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2 2024 ·JCO Precision Oncology ·Erica S. Tsang, (unknown), (unknown), Scott Thomas, Jennifer A. Grabowsky, (unknown), (unknown), Robin Kate Kelley, Andrew H. Ko, Eric A. Collisson, Jocelyn Chapman, Stefanie Ueda, Emily K. Bergsland, Pamela N. Münster	1
2	Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies 2024 ·JCO Precision Oncology ·Erica S. Tsang, Rahul Aggarwal, Emily K. Bergsland, (unknown), (unknown), (unknown), (unknown), Nela Pawłowska, Jennifer A. Grabowsky, Scott Thomas, Pamela N. Münster	2
3	Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas 2023 ·British Journal of Cancer ·Nitya Raj, Jennifer A. Chan, Stephanie J. Wang, Rahul Aggarwal, (unknown), (unknown), Lawrence Fong, Jennifer A. Grabowsky, Thomas A. Hope, K. Kolli, Claire K. Mulvey, Pamela N. Münster, Kimberly Perez, (unknown), Diane Reidy‐Lagunes, (unknown), Li Zhang, Emily K. Bergsland	6
4	A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies 2022 ·Cancer Research Communications ·Erica S. Tsang, Rahul Aggarwal, (unknown), Emily K. Bergsland, Edwin Alvarez, (unknown), (unknown), (unknown), (unknown), Scott Thomas, Jennifer A. Grabowsky, Mark M. Moasser, Pamela N. Münster	6
5	Updated survival follow-up for phase I study of abexinostat with pazopanib in patients with solid tumor malignancies. 2022 ·Journal of Clinical Oncology ·Erica S. Tsang, Rahul Aggarwal, Scott Thomas, (unknown), Nela Pawłowska, Imke H. Bartelink, Jennifer A. Grabowsky, Thierry Jahan, Thach‐Giao Truong, Charles J. Ryan, Pamela N. Münster	1
6	Phase I study of rucaparib and irinotecan in advanced solid tumors with homologous recombination deficiency (HRD) mutations. 2020 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Rahul Aggarwal, Jennifer A. Grabowsky, Pamela N. Münster	4
7	Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone). 2019 ·Journal of Clinical Oncology ·Claire K. Mulvey, Nitya Raj, Jennifer A. Chan, Rahul Aggarwal, Pelin Cinar, Thomas A. Hope, K. Kolli, Li Zhang, (unknown), Jennifer A. Grabowsky, (unknown), (unknown), (unknown), Pamela N. Münster, Diane Reidy‐Lagunes, Lawrence Fong, Emily K. Bergsland	18
8	Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study. 2019 ·Journal of Clinical Oncology ·Rahul Aggarwal, Scott Thomas, Nela Pawłowska, Jennifer A. Grabowsky, (unknown), (unknown), (unknown), (unknown), Pamela N. Münster	6
9	Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA). 2019 ·Journal of Clinical Oncology ·Pamela N. Münster, Jasgit C. Sachdev, Gini F. Fleming, Erkut Borazanci, Jennifer A. Grabowsky, Manish Sharma, Joseph M. Custodio, Andrew E. Greenstein, Lawrence Lu, Dat Nguyen, Stacie Peacock Shepherd	5
10	Abstract A173: Long-term responders to epigenetic modulators: abexinostat and pazopanib 2018 ·Molecular Cancer Therapeutics ·Rahul Aggarwal, (unknown), Jennifer A. Grabowsky, (unknown), (unknown), Scott Thomas, Pamela N. Münster	1
11	Phase 1 study of ANDES-1537: A novel antisense oligonucleotide against non-coding mitochondrial DNA in advanced solid tumors. 2018 ·Journal of Clinical Oncology ·(unknown), Rahul Aggarwal, (unknown), (unknown), (unknown), (unknown), Pablo Valenzuela, Jennifer A. Grabowsky, Scott Thomas, Pamela N. Münster	20
12	Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies 2017 ·Journal of Clinical Oncology ·Rahul Aggarwal, Scott Thomas, Nela Pawłowska, Imke H. Bartelink, Jennifer A. Grabowsky, Thierry Jahan, Amy Cripps, (unknown), Jim Leng, (unknown), (unknown), (unknown), Charles J. Ryan, Pamela N. Münster	76
13	Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors 2017 ·Clinical Cancer Research ·(unknown), Imke H. Bartelink, Rahul Aggarwal, Jim Leng, (unknown), Nela Pawłowska, Manuela Terranova-Barberio, Jennifer A. Grabowsky, (unknown), A. Jo Chien, Mark M. Moasser, Robin Kate Kelley, (unknown), Scott Thomas, Pamela N. Münster	58
14	A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma 2016 ·Annals of Oncology ·Scott Thomas, Rahul Aggarwal, Thierry Jahan, Charles J. Ryan, (unknown), Amy Cripps, Paromita Raha, Kenneth T. Thurn, (unknown), Jennifer A. Grabowsky, (unknown), Jimee Hwang, Adil Daud, Pamela N. Münster	24
15	A phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (pts) with metastatic solid tumors. 2015 ·Journal of Clinical Oncology ·Rahul Aggarwal, Jennifer A. Grabowsky, (unknown), Scott Thomas, Thach‐Giao Truong, (unknown), Pamela N. Münster	1
16	Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors 2015 ·Journal of Clinical Oncology ·Adil Daud, Michelle T. Ashworth, Jonathan Strosberg, Jonathan W. Goldman, David S. Mendelson, Gregory M. Springett, Alan P. Venook, (unknown), Lee S. Rosen, Fergus Shanahan, David Parry, Stuart D. Shumway, Jennifer A. Grabowsky, Tomoko Freshwater, Christopher L. Sorge, Soonmo Peter Kang, Randi Isaacs, Pamela N. Münster	153
17	Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies 2014 ·Cancer Chemotherapy and Pharmacology ·Rahul Aggarwal, Jennifer A. Grabowsky, (unknown), (unknown), Pamela N. Münster	8
18	Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates 2013 ·Annals of Oncology ·Robin Kate Kelley, Halla Nimeiri, P.N. Munster, Maxwell T. Vergo, (unknown), Caixia Li, Justin H. Hwang, Mary F. Mulcahy, Benjamin M. Yeh, Peter Kühn, Madelyn Luttgen, Jennifer A. Grabowsky, (unknown), W. Michael Korn, Andrew H. Ko, Emily K. Bergsland, Al B. Benson, Alan P. Venook	50
19	Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer. 2013 ·Journal of Clinical Oncology ·A. Jo Chien, Thach‐Giao Truong, Michelle Melisko, Mark M. Moasser, Robin Katie Kelley, Michael Korn, Andrew H. Ko, (unknown), (unknown), Jennifer A. Grabowsky, Mark Jesus M. Magbanua, Hope S. Rugo, Pamela N. Münster	3
20	Quantification of Inflammatory Mediators in Stool Samples of Patients with Inflammatory Bowel Disorders and Controls 1997 ·Digestive Diseases and Sciences ·Stephan C. Bischoff, Jennifer A. Grabowsky, Michael P. Manns	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact